Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01917383 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
A Phase 2 study, sponsored by Inotek Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT01917383 is a Phase 2 study that has completed, run by Inotek Pharmaceuticals Corporation. The registered enrollment target is 101 participants.
The verdict
NCT01917383, a Phase 2 study, has completed, sponsored by Inotek Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering efficacy and the safety and tolerability profile of trabodenoson ophthalmic formulation compared to timolol maleate ophthalmic solution 0.5% in adults with ocular hypertension (OHT) or primary open-angle glaucoma (POAG) who are already receiving treatment with latanoprost ophthalmic solution 0.005% once every evening (QPM).
Interventions
- DRUG Latanoprost
- DRUG Timolol
- DRUG Trabodenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01917383
The ClinicalTrials.gov registry entry for NCT01917383 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inotek Pharmaceuticals Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Latanoprost is the first listed.
NCT01917383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01917383 about?
NCT01917383 is a clinical study titled "A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma". The purpose of this study is to evaluate the intraocular pressure (IOP) lowering efficacy and the safety and tolerability profile of trabodenoson ophthalmic formulation compared to timolol maleate ophthalmic solution 0.5% in adults with ocular hypertension (OHT) or primary open-angle glaucoma (POAG)...
What is the current status of trial NCT01917383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2013-08. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01917383?
The interventions under investigation include: Latanoprost (DRUG), Timolol (DRUG), Trabodenoson (DRUG).
Who is sponsoring clinical trial NCT01917383?
This trial is sponsored by Inotek Pharmaceuticals Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.